Biologics manufacturing is in the middle of a generational shift, moving away from the batch-oriented, stainless-steel-heavy processes that dominated for decades toward continuous, data-driven, and increasingly flexible production platforms. The changes span every stage of making a biologic, from how cells are engineered and grown to how the final product is purified, formulated, and tested for release. What makes this moment distinct is that several advances are converging at once: gene-editing tools that reshape production cell lines, single-use hardware that slashes facility build times, real-time sensors that replace slow lab assays, and digital models that predict process outcomes before a run even starts. The result is a manufacturing landscape that looks fundamentally different from what existed even ten years ago.
Perfusion Culture and Intensified Upstream Processing
Most therapeutic antibodies are still made using fed-batch culture, where cells grow in a bioreactor, get fed nutrients over a period of days to weeks, and are harvested all at once. It works, but it ties up large bioreactors for long stretches and limits how much product you can squeeze out of a given facility footprint. The alternative gaining ground is perfusion culture, where fresh media continuously flows into the bioreactor and spent media (carrying the product) is continuously drawn off, while the cells stay behind. This keeps cells at much higher densities for longer periods and produces a steady stream of product rather than a single batch.
A techno-economic analysis comparing perfusion using alternating tangential flow (ATF) filtration against conventional fed-batch found that perfusion could cut cost of goods by about 20% when cell densities reached five times those of fed-batch. Even at a more conservative threefold increase in cell density, cost savings persisted across most combinations of product concentration and production scale.1PubMed. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty The savings come from smaller bioreactors doing the same work as larger ones, plus a steadier harvest that makes downstream equipment easier to size. The trade-off is operational complexity: perfusion runs can stretch for weeks or months and demand tighter process control, which is one reason the approach has been slower to gain regulatory acceptance than its economic case might suggest.
CRISPR-Engineered Cell Lines
Chinese hamster ovary (CHO) cells remain the workhorse for producing monoclonal antibodies and many other biologics. What has changed is how manufacturers optimize them. Rather than relying solely on traditional screening and selection, labs now use CRISPR-based tools to directly edit CHO genomes, knocking out genes that limit productivity or tweaking pathways that control how sugars are attached to the protein product. Those sugar modifications matter because they influence how a drug behaves in the body, so controlling them through genetic engineering gives manufacturers a tighter handle on product quality.2PubMed. Improving recombinant protein production in CHO cells using the CRISPR-Cas system
One particularly creative application is CRISPR interference (CRISPRi), which does not cut the DNA at all but instead dials down gene activity. Researchers used CRISPRi to suppress a selection-marker gene in CHO cells, forcing cells under selective pressure to amplify copies of both the marker gene and the therapeutic gene riding alongside it. The result was roughly a 3.8-fold increase in expression of a model protein and about a 2.3-fold boost in production of granulocyte colony-stimulating factor, a therapeutic protein, without harming cell growth.3PubMed. Enhancing Protein Production Yield from Chinese Hamster Ovary Cells by CRISPR Interference These are still relatively early demonstrations, but they point toward a future where cell line development is faster and more predictable than the laborious clone-screening campaigns of the past.
Single-Use Technology and Its Evolving Footprint
Walk into a modern biologics facility and you will see far less stainless steel than you might expect. Single-use bioreactors (SUBs), tubing, filters, and mixing bags have replaced fixed equipment in many operations, especially for clinical-scale and multi-product sites. The appeal is straightforward: no cleaning or sterilization between batches, lower upfront capital costs, faster changeover between products, and reduced risk of cross-contamination.4Food and Bioproducts Processing. Single-use in the biopharmaceutical industry: A review of current technology impact, challenges and limitations Studies have confirmed that single-use bioreactors can grow a range of cell types, including antibody-producing lines, with results comparable to their traditional counterparts.5Food Bioengineering. Bioprocess strategies for enhanced performance in single‐use bioreactors for biomolecule synthesis: A biokinetic approach
The environmental story is more nuanced than people assume. Early life-cycle assessments consistently showed single-use process trains having lower environmental impacts than stainless-steel equivalents, mainly because they eliminated the energy-hungry generation of purified water and clean steam needed for cleaning.6Journal of Cleaner Production. An environmental life cycle assessment comparison of single-use and conventional process technology for the production of monoclonal antibodies A recent laboratory-scale comparison confirmed that single-use bioreactors produced a lower carbon footprint and used less water than stainless steel, regardless of end-of-life disposal method.7Journal of Cleaner Production. Comparative life cycle assessment of stainless steel and single-use bioreactor units: A laboratory scale case study However, a newer bottom-up analysis of real-world facilities found that the CO₂ footprint of single-use technology is higher than older estimates suggested, with filters and bags identified as emission hotspots. As electricity grids get cleaner, the energy penalty of cleaning stainless steel shrinks, and certain stainless-steel process steps now have a lower carbon footprint than their single-use equivalents. The study concluded that an optimized hybrid facility design, mixing single-use and stainless-steel components, offers the best combination of reduced plastic waste and lower emissions.8PubMed Central. Revisiting the Carbon Footprint of Single-Use Technologies in Biomanufacturing: A Bottom-Up Analysis Reveals a Paradigm Shift This is a space where received wisdom is shifting fast, and blanket statements about one technology being “greener” no longer hold.
Real-Time Monitoring with Raman Spectroscopy
One of the quieter revolutions in biologics manufacturing is the replacement of slow, offline lab samples with real-time spectroscopic sensors. Raman spectroscopy, in particular, has emerged as a versatile inline tool: a laser probe sits inside or against the bioreactor, and the scattered light it collects carries chemical fingerprints of dozens of compounds in the culture. Researchers have built calibration models for 27 different components in a single bioreactor, spanning amino acids, organic acids, sugars, protein titer, and cell density, with strong predictive accuracy across nearly all of them. The same system could detect abnormal conditions like bacterial contamination or insufficient feeding using statistical control charts.9Process Biochemistry. Comprehensive cell culture monitoring: Leveraging in-line Raman spectroscopy for enhanced biopharmaceutical manufacturing insights
Beyond process control, the sustainability case for inline Raman is surprisingly strong. A study quantifying the impact of switching from traditional offline sampling found that inline Raman monitoring eliminated roughly 13 kg of single-use plastic and prevented about 80 kg of CO₂ emissions per combined run at small and large scale, while also reducing contamination risk by keeping the system closed.10Journal of Chemical Technology & Biotechnology. Sustainability impacts for converting to Raman spectroscopy inline monitoring from traditional offline manual sampling in small‐scale and large‐scale biomanufacturing That is a tangible benefit that stacks up across hundreds of runs per year in a busy facility.
Digital Twins and Machine Learning
A digital twin in biomanufacturing is a virtual replica of a physical process, continuously updated with real data, that can predict what will happen next and suggest corrective actions before a problem shows up in the bioreactor. These models are increasingly built by combining classical mechanistic equations (describing cell growth, nutrient consumption, and product formation) with machine-learning algorithms that capture patterns too subtle for traditional models. When paired with AI, digital twins enable predictive maintenance and process optimization that would be impractical through conventional approaches alone.11PubMed Central. Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives
A persistent challenge has been data scarcity. Building a high-fidelity digital twin for a new bioprocess normally requires many experimental runs, which are expensive and slow. Transfer learning offers a shortcut: a model trained on data from an existing process is adapted to a new one using only a handful of runs. A recent study combining hybrid mechanistic-ML modeling with transfer learning showed significantly better predictions and lower uncertainty than a purely kinetic model, even with limited data from the new process.12Chemical Engineering Journal. Accelerating bioprocess digital twin development by integrating hybrid modelling with transfer learning If this approach matures, it could dramatically shorten the time it takes to stand up a manufacturing process for a new biologic.
End-to-End Continuous Manufacturing
Running each unit operation continuously is one thing; connecting them all into a seamless, uninterrupted flow from bioreactor to final product is another. End-to-end continuous biomanufacturing is arguably the most ambitious goal in the field, and the economic and environmental case for it keeps getting stronger. One comprehensive assessment found that, compared with a best-in-class fed-batch process already using high titers and multicolumn chromatography, a fully continuous monoclonal antibody process could reduce annual production costs by up to 23%, facility footprint by 51%, plastic waste by 57%, and CO₂ emissions by 54% in a multi-product facility.13Trends in Biotechnology. Advancing biopharmaceutical manufacturing: economic and sustainability assessment of end-to-end continuous production of monoclonal antibodies Those advantages grew even larger when demand fluctuated, since continuous facilities can adjust throughput more easily than batch plants.
Designing such a platform requires integrating intensified seed expansion, high-density perfusion, single-pass tangential flow filtration, and single-use components into one harmonized workflow. A process-design study that modeled a fully integrated continuous platform at a 500-liter bioreactor scale calculated a cost of goods of about $102 per gram of antibody, a figure that reflects both the efficiency gains and the operational intensity of running everything in continuous mode.14PubMed. Process design of a fully integrated continuous biopharmaceutical process using economic and ecological impact assessment The broader industry picture is encouraging: over 15 pharmaceutical products manufactured through continuous processes have obtained FDA approval, supported by the ICH Q13 regulatory guideline that provides a harmonized framework for continuous manufacturing applications.15Discover Applied Sciences. Continuous pharmaceutical manufacturing and its contemporary regulatory insights Still, most of those approvals are for small-molecule drugs. Fully continuous biologic manufacturing at commercial scale remains more aspiration than norm, though the regulatory path is now much clearer than it was a decade ago.
Viral Vector and CAR T Cell Production
Gene therapies and cell therapies depend on manufacturing challenges quite different from those of antibodies. Viral vectors such as adeno-associated virus (AAV) and lentivirus need to be produced in enormous quantities, yet they are far more delicate than a monoclonal antibody and cannot survive the same harsh purification steps. Scaling AAV production has seen real progress: one group adapted an adherent HEK293 cell line from a clinical master cell bank to grow in suspension in animal-component-free media, enabling scalable production in WAVE bioreactors.16Molecular Therapy. Scalable and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale A complementary approach uses baculovirus-infected insect cells in suspension, with successful demonstrations from shake flasks up to 20-liter bioreactors, though optimization at high cell densities remains a work in progress.17PubMed. Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor
For lentiviral vectors used in CAR T therapies, a scalable suspension process using transient transfection of HEK293 cells demonstrated the ability to generate more than 100 billion functional vector particles in a single bioreactor run.18PubMed. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures On the CAR T manufacturing side, the push is toward full automation. Closed, modular platforms now offer end-to-end processing of autologous CAR T cells, from fresh or frozen apheresis starting material all the way to final patient doses, using dedicated single-use kits and integrated software.19Cytotherapy. END-TO-END AUTOMATED MANUFACTURING OF AUTOLOGOUS CAR T CELL THERAPIES WITH THE NEW SEFIA™ CELL THERAPY MANUFACTURING PLATFORM Automation matters here not just for throughput but for consistency: autologous cell therapies are inherently variable because every patient’s starting cells are different, so removing human hands from the process reduces one source of variability.
Scaling Up mRNA-Lipid Nanoparticle Production
The COVID-19 vaccines proved that mRNA therapeutics can be manufactured at breathtaking speed, but the production technology still has room to mature. mRNA drugs are formulated inside lipid nanoparticles (LNPs), tiny fat-based shells that protect the fragile RNA and deliver it into cells. Making those LNPs with consistent size and composition is a precision mixing problem, and the industry is converging on microfluidic devices as the solution. A parallelized microfluidic chip incorporating up to 256 mixing units has demonstrated scalable production rates of up to 17 liters per hour, with LNP physical properties and potency in animal models unchanged as throughput scaled up.20PubMed Central. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
The stumbling block for microfluidics at industrial scale has been fouling: lipid and protein residues accumulate on channel walls during extended runs, degrading performance over hours. An antifouling lubricant coating applied to the device surfaces has shown promise in addressing this, maintaining stable production at liter-per-hour rates on a 256-mixer platform.21ACS Nano. Robust, Scalable Microfluidic Manufacturing of RNA–Lipid Nanoparticles Using Immobilized Antifouling Lubricant Coating If fouling can be reliably solved, microfluidic LNP production could become the standard manufacturing method for mRNA vaccines and therapies, replacing the turbulent bulk-mixing approaches that sacrifice some control over particle uniformity.
Clearing Host Cell Contaminants
No matter how productive a cell line is, the raw harvest from a bioreactor is a complex soup containing not just the desired biologic but thousands of host cell proteins (HCPs), DNA fragments, and other impurities. Removing HCPs to very low levels is essential for drug safety. The challenge is getting harder in one respect: as manufacturers push cells to higher densities and titers, HCP levels in the harvest rise in parallel. Fortunately, improvements in downstream operations have kept pace, and meta-analysis of published data shows that current processes can bring final HCP levels down to roughly 10 parts per million.22PubMed. Host cell proteins in monoclonal antibody processing: Control, detection, and removal
Emerging purification methods are pushing clearance even further. High-performance countercurrent membrane purification, for instance, demonstrated over 100-fold reduction in HCPs with antibody recovery above 95%, maintaining stable operation for 48 hours on pre-filtered feed.23PubMed. High-performance countercurrent membrane purification for host cell protein removal from monoclonal antibody products On the analytical side, mass-spectrometry-based methods like SWATH are providing a sharper picture of which specific HCPs survive purification and at what levels, with absolute quantification reaching limits as low as a few parts per million for individual high-risk proteins.24PubMed. SWATH-MS as a strategy for CHO host cell protein identification and quantification supporting the characterization of mAb purification platforms Better analytics and better removal feed into each other: when you can identify the specific troublemaking proteins, you can tailor your purification to target them.
High-Concentration Formulations for Subcutaneous Delivery
Manufacturing a biologic does not end when the molecule is purified. Increasingly, the formulation step presents its own set of engineering headaches, especially for antibodies intended for subcutaneous injection rather than intravenous infusion. Subcutaneous delivery is strongly preferred by patients and healthcare systems alike because it is faster, can be self-administered, and frees up clinic chairs. But the volume you can inject under the skin is small, which means the antibody concentration in the vial has to be very high, often above 100 or even 150 mg/mL. At those concentrations, protein solutions become extremely viscous, difficult to manufacture, and prone to instability from molecular crowding effects.25PubMed Central. Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment
The search for excipients that lower viscosity without harming protein stability is ongoing. Amino acid salts, particularly arginine hydrochloride, have shown the most consistent benefit. A proof-of-concept study demonstrated that liquid-liquid phase separation could be used to concentrate an antibody above 170 mg/mL without altering its structure, and that adding arginine-glutamate to the resulting dense fraction produced a stable formulation with reduced viscosity and no further phase separation.26PubMed Central. Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation If approaches like these become routine, they could unlock subcutaneous delivery for antibodies that currently require IV infusion simply because nobody has solved the formulation puzzle yet.
Cell-Free Protein Synthesis
An entirely different manufacturing paradigm dispenses with living cells altogether. Cell-free protein synthesis (CFPS) uses the extracted molecular machinery of cells, ribosomes, enzymes, energy sources, and amino acids, in a test tube to build proteins on demand. The practical advantage is that CFPS reactions can be freeze-dried into shelf-stable pellets that require no refrigeration, stored for months, and then rehydrated wherever and whenever needed. This opens the door to decentralized production of therapeutics such as antibody-drug conjugates, vaccine antigens, and antimicrobial peptides, potentially useful in remote settings or emergency responses.27PubMed Central. Advancing synthetic biology through cell-free protein synthesis
Researchers have demonstrated thermostable, low-cost cell-free systems for producing conjugate vaccines, reinforcing the idea that CFPS could complement traditional manufacturing in contexts where cold-chain logistics are a barrier.28ACS Synthetic Biology. A Low-Cost, Thermostable, Cell-Free Protein Synthesis Platform for On-Demand Production of Conjugate Vaccines CFPS is not about to replace CHO cells for making tons of antibody, but it occupies a genuinely different niche: small batches, rapid turnaround, and independence from large centralized infrastructure.
Faster Sterility Testing and Batch Release
One of the more underappreciated bottlenecks in biologics manufacturing is quality-control release testing. The standard compendial sterility test requires a 14-day incubation to confirm that no microorganisms are growing in the final product. For short-shelf-life products like cell therapies, where the drug may need to reach the patient within days of production, waiting two weeks is functionally impossible and often means releasing product at risk, before the test result is in. A novel approach using isothermal microcalorimetry detected microbial contamination faster and with higher sensitivity than the traditional method. The calorimetry device identified a higher percentage of positive samples (about 96% versus 88%) and cut average detection times roughly in half, from 43 hours down to 19 hours at the higher inoculum level tested.29bioRxiv. Evaluation of a novel isothermal microcalorimetry-based sterility test Speed and sensitivity moving in the same direction is unusual for a new analytical method, and if validated more broadly, this kind of rapid test could remove a significant logistical headache for autologous cell therapy manufacturers.
Media Variability and Supply Chain Resilience
All the bioreactor engineering and downstream innovation in the world cannot rescue a process if the raw materials going in are inconsistent. Cell culture media is the single largest raw-material input for most biologics processes, and variability in its components can alter cell growth, product yield, and even the quality profile of the therapeutic protein. The industry has largely moved from serum-containing to chemically defined media to reduce this variability, but even chemically defined formulations are not immune to lot-to-lot differences in their individual chemical ingredients.30PubMed. Examining the sources of variability in cell culture media used for biopharmaceutical production Supply chain disruptions during the pandemic underscored just how dependent biologics production is on a narrow set of specialty chemical and single-use component suppliers. Building redundancy into the supply chain, qualifying secondary suppliers for critical media components, and developing more robust media formulations remain active areas of industry attention, even if they lack the glamour of gene editing or digital twins.